AOD-9604 side effects and results in studies
The AOD-9604 abstracts on file report no adverse events, and none of them describe a human trial. The measured results are animal outcomes: lower weight gain and body fat in obese rodents, unchanged insulin sensitivity in rats, and better cartilage scores in a rabbit knee model.
Adverse events reported
| Event | As reported | Source |
|---|---|---|
| Insulin sensitivity | No adverse effect after 19 days of daily oral AOD9604 in obese Zucker rats (euglycaemic clamp), in contrast to chronic intact hGH | Ng FM et al. |
Outcomes measured
| Outcome | Result as reported | Source |
|---|---|---|
| Body weight gain (obese Zucker rats, 19 days oral) | 15.8 ± 0.6 g with AOD9604 vs 35.6 ± 0.8 g in controls, a reduction of over 50% | Ng FM et al. |
| Adipose tissue lipolytic activity (rats) | Increased in AOD9604-treated animals | Ng FM et al. |
| Body weight and body fat (obese mice, 14 days ip) | Reduced by both hGH and AOD9604 | Heffernan M et al. |
| Beta3-adrenergic receptor RNA in fat (obese mice) | Raised from repressed levels to levels comparable with lean mice | Heffernan M et al. |
| Body weight and lipolysis (beta3-AR knock-out mice, chronic) | No change, unlike wild-type controls | Heffernan M et al. |
| Energy expenditure and fat oxidation (knock-out mice, acute) | Increased with AOD9604 | Heffernan M et al. |
| Cartilage morphology and histopathology scores (rabbit knee OA) | Better than saline with AOD9604 alone; best with AOD9604 plus hyaluronic acid | Kwon DR et al. |
| Lameness period (rabbit knee OA) | Shortest with AOD9604 plus hyaluronic acid; saline group longest | Kwon DR et al. |
| Cumulative body weight gain and fat mass (ob/ob mice, hGH 177-191) | Both reduced; adipose lipogenesis significantly inhibited | Natera SH et al. |
What the studies don't show
There are no before-and-after results in people here: every outcome was measured in rats, mice or rabbits, mostly over 2–3 weeks. The abstracts do not report side effects in any detail, so the absence of reported adverse events is not evidence of safety. Human trial results are not among the records on file.